Attia v. Oura Ring, Inc. et al

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
United States District Court
Northern District of California
UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF CALIFORNIA
PETER ATTIA,
Plaintiff,
v.
OURARING INC., et al.,
Defendants.
Case No. 23-cv-03433-HSG (LJC)
ORDER RESOLVING ECF NO. 114
Re: Dkt. No. 114
Before the Court is Plaintiff Dr. Peter Attia’s and Defendants Oura Health Ltd. (Oura
Health)1 and Oura Ring, Inc.’s joint discovery letter disputing whether Plaintiff may depose Oura
Health’s Chief Legal Officer and Corporate Secretary, Avonte Campinha-Bacote, and whether Mr.
Campinha-Bacote must produce his communications with Defendants’ board members and
employees. ECF No. 114. For the following reasons, Plaintiff’s request to depose Mr. Campinha-
Bacote and for production of Mr. Campinha-Bacote’s communications with current and former
employees and members of Defendants’ Board is denied.
I. BACKGROUND
Defendants are the entities behind Oura Ring, a wearable device that tracks users’ health
metrics. Plaintiff is a physician-turned-wellness-guru who alleges that he served as an advisor for
Defendants pursuant to an agreement with Defendants’ former CEO, Harpreet Rai. ECF No. 75
(Second Am. Compl.) ¶¶ 28, 36, 41. Specifically, Plaintiff alleges that in October 2018, Mr. Rai
emailed Plaintiff to inform him that Defendants’ Board approved issuing Plaintiff stock options
1 Defendants identify this entity as “Oura Health Oy” rather than “Oura Health Ltd.” See ECF No.
89 at 2. “Oy” is apparently the Finnish translation of “Ltd.” See ECF No. 16-1 ¶ 2. The Court
refers to this entity as Oura Health.
Case 4:23-cv-03433-HSG Document 125 Filed 10/21/25 Page 1 of 8

2
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
United States District Court
Northern District of California
“equal to [Plaintiff’s] previous total investments” in the company. Id. ¶¶ 45-47. Mr. Rai sent
Plaintiff a stock option agreement (Stock Option Agreement), which Plaintiff signed in February
2019. Id. ¶¶ 49-50. Plaintiff alleges that he continued to provide medical and technical advice to
Defendants and promoted Oura Ring products to his social media followers based on his
understanding that he would be compensated for his work pursuant to the Stock Option
Agreement. See Id. ¶¶ 55, 61-69. Mr. Rai left Defendants in December 2021, and, Plaintiff
alleges, Defendants have refused to honor the Stock Option Agreement. Id. ¶¶ 73-80. Defendants
allege, among other things, that their Board never agreed to the Stock Option Agreement, that the
Agreement is invalid under Finnish and American laws, and that Plaintiff is barred under the
doctrines of unclean hands and estoppel from recovering against them. See ECF No. 89 (Am.
Answer to Second Am. Compl.) at 9-16.
Mr. Campinha-Bacote is Defendant Oura Health’s Chief Legal Officer and Corporate
Secretary. ECF No. 100-7 (Campinha-Bacote Decl.) ¶ 1. He has held these positions since
January 2024. Id. He served as Oura Health’s General Counsel from February 2020 to December
2023. Id. In his current role, he oversees “all of Oura Health’s legal matters” and advises and
consults “with Oura Health’s management and Board.” Id. During the course of this litigation,
Mr. Campinha-Bacote has submitted two declarations: one in support of Defendants’ motion to
compel arbitration (ECF No. 16-1), and one in support of Defendants’ motion to retain their
Attorneys’ Eyes-Only designation of certain documents (ECF No. 100-7). In his declaration in
support of the motion to compel arbitration, Mr. Campinha-Bacote attested:
In my capacity as the General Counsel for the Defendants, I am aware
that in Plaintiff’s Complaint he claims that on February 18, 2019, he
signed and sent a copy of a document called “Oura Health Oy/Oura
Ring, Inc. Adviser Equity Plan 2018 US Stock Option Agreement”
(hereinafter “Draft Agreement”) to Defendants. (DKT # 1 -
Complaint, ¶ 50). However, I am also aware that the Draft Agreement
was never authorized or approved by Oura Health Oy’s (or Ouraring
Inc.’s) Board of Directors, and was never executed by anyone at either
company.
ECF No. 16-1 ¶ 14. In his declaration in support of the motion to retain the confidentiality
designation, Mr. Campinha-Bacote attested:
I am informed and believe that at various times in 2024, Dr. Attia
Case 4:23-cv-03433-HSG Document 125 Filed 10/21/25 Page 2 of 8

3
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
United States District Court
Northern District of California
baselessly accused a Board member of having a conflict of interest,
and more generally accused Oura Health or its Board members of
engaging in fraud. I and many members of the Board believe that Dr.
Attia’s accusations caused certain influential shareholders to
withdraw support for a major Board initiative, which was detrimental
to the company’s interests.
ECF No. 107-3 ¶ 8.
Plaintiff argues that they must be permitted to depose Mr. Campinha-Bacote to question
him “about his personal knowledge of these allegations, and his communications with current and
former Board members and Oura employees about them,” and that Mr. Campinha-Bacote should
be compelled to produce his “communications with current and former Board members and Oura
employees about these allegations.” ECF No. 114 at 3. Defendants counter that there is no legal
basis for Plaintiff to depose Mr. Campinha-Bacote or obtain his confidential communications with
Defendants’ Board. Id.
II. LEGAL STANDARD
Federal Rule of Civil Procedure 30 provides that “[a] party … may depose any person.”
Thus, there is no express prohibition against deposing attorneys. See Graff v. Hunt & Henriques,
No. C 08-0908, 2008 WL 2854517, at *1 (N.D. Cal. July 23, 2008). Defendants contend that
attorney depositions are nonetheless disfavored and urges the Court to apply the three-part test
established in Shelton v. American Motors Corporation, 805 F.2d 1323 (8th Cir. 1986), to
determine whether Mr. Campinha-Bacote’s deposition may take place. ECF No. 114 at 3. The
Shelton test provides that for a court to allow an opposing trial counsel’s deposition, the party
seeking to take the deposition must show that: “(1) no other means exist to obtain the information
than to depose opposing counsel; (2) the information sought is relevant and nonprivileged; and (3)
the information is crucial to the preparation of the case.” 805 F.2d at 1327 (citation omitted).
This Court has applied Shelton to deny requests to depose opposing trial counsel. See Serenity
Investments v. Sun Hung Strategic Capital, No. 22-cv-01623, 2024 WL 517870, at *5 (N.D. Cal.
Feb. 9, 2024). Unlike in Serenity Investments, here Plaintiff seeks to depose and obtain documents
from Oura Health’s Chief Legal Officer, not Defendants’ trial counsel in the instant case. Absent
a showing that Mr. Campinha-Bacote has particular knowledge of Defendants’ trial counsel’s
litigation strategy, it is not clear why Shelton would apply. See Textron Fin. Corp. v. Gallegos,
Case 4:23-cv-03433-HSG Document 125 Filed 10/21/25 Page 3 of 8

4
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
United States District Court
Northern District of California
No. 15cv1678, 2016 WL 4169128, at *2 (S.D. Cal. Aug. 5, 2016) (“However, the Shelton test is
not necessarily applicable in a situation where the attorney sought to be deposed is not litigation
counsel in the pending case.”); Mass. Mut. Life Ins. Co. v. Cerf, 177 F.R.D. 472, 479 (N.D. Cal.
1998) (explaining the Shelton test before determining that it did not apply because the attorney at
issue “did not represent [Defendant] in this action”).2
The Court instead applies the usual standards of Federal Rule of Civil Procedure 26. Rule
26(b)(1) provides:
Parties may obtain discovery regarding any nonprivileged matter that
is relevant to any party’s claim or defense and proportional to the
needs of the case, considering the importance of the issues at stake in
the action, the amount in controversy, the parties’ relative access to
relevant information, the parties’ resources, the importance of the
discovery in resolving the issues, and whether the burden or expense
of the proposed discovery outweighs its likely benefit.”
The court must “limit the frequency or extent of discovery” if it determines that the information
sought is “outside the scope permitted by Rule 26(b)(1)” or is “unreasonably cumulative or
duplicative, or can be obtained from some other source that is more convenient, less burdensome,
or less expensive.” Fed. R. Civ. P. 26(b)(2)(C). “The court may, for good cause, issue an order to
protect a party or person from annoyance, embarrassment, oppression, or undue burden or
expense.” Fed. R. Civ. P. 26(c)(1).
III. ANALYSIS
Plaintiff seeks to question Mr. Campinha-Bacote about his statements that the Stock
Option Agreement “was never authorized or approved” by Defendants’ Board and that he believes
Plaintiff’s accusations against a Board member “caused certain influential shareholders to
withdraw support for a major Board initiative,” as well as his “communications with current and
former Board members and Oura employees.” ECF Nos. 16-1 ¶ 14, 107-3 ¶ 8, 114 at 3. Plaintiff
also seeks Mr. Campinha-Bacote’s “communications with current and former Board members and
2Although Shelton involved the deposition of the defendants’ in-house counsel Rita Burns, Ms.
Burns “was assigned specifically to the case at bar” and was involved in preparing her client’s
defense in the action. 805 F.2d at 1325, 1328. The Eighth Circuit’s holding concerned protecting
trial counsel from being forced “to testify as a witness” and reveal their “legal theories and
strategy” in the pending case. Id. at 1327.
Case 4:23-cv-03433-HSG Document 125 Filed 10/21/25 Page 4 of 8

5
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
United States District Court
Northern District of California
Oura employees,” which Defendants have objected to producing on the basis of attorney-client
privilege. ECF Nos. 114 at 3, 114-1 at 3-4.
Plaintiff has not shown that Mr. Campinha-Bacote, who joined Defendants in 2020, would
have relevant information regarding whether the Board “authorized or approved” the Stock Option
Agreement, which Plaintiff alleges he received and signed in early 2019. ECF No. 16-1 ¶ 14; see
Second Am. Compl. ¶¶ 49-50. But even accepting that Plaintiff seeks relevant information,
Defendants have shown that obtaining discovery from Mr. Campinha-Bacote is otherwise
improper under Rule 26. Defendants object that the discovery Plaintiff seeks is protected by
attorney-client privilege. See ECF No. 114 at 3; 114-1 at 3-4. Plaintiff does not dispute that the
information he seeks is privileged, instead arguing that Mr. Campinha-Bacote waived this
privilege by submitting the two declarations. ECF No. 114 at 2. Plaintiff claims:
Campinha-Bacote and Oura voluntarily submitted declarations
regarding the Board’s knowledge as to Attia’s option agreement and
Oura’s accusations that Attia “undermined” and “interfered” with the
Board, and caused the failure of a “major Board initiative.” These
statements go to the heart of Oura’s defenses, and Campinha-Bacote
has obviously communicated with the Board about these matters. By
submitting his declarations, Oura waived its privilege as to those
communications.
Id. As the Court has diversity jurisdiction over this case, California law regarding the existence
and scope of attorney-client privilege applies. In re California Pub. Utilities Comm’n, 892 F.2d
778, 781 (9th Cir. 1989) (“In diversity actions, questions of privilege are controlled by state
law.”); Fed. R. Evid. 501 (establishing that in civil cases, “state law governs privilege regarding a
claim or defense for which state law supplies the rule of decision”); see Second Am. Compl. ¶ 6
(alleging that the Northern District has diversity jurisdiction over this action). The Court
accordingly applies California law to determine if there has been a waiver of attorney-client
privilege.3
3 In contrast, if the Court determines that there has been a waiver, it would consider federal law to
determine the scope of the waiver. See Century Aluminum Co. v. AGCS Marine Ins. Co., 285
F.R.D. 468, 471 n.2 (N.D. Cal. 2012) (“The Federal Rules of Evidence govern the scope of waiver
even if state law provides the rule of decision.”). Federal Rule of Evidence 502 applies “to
disclosure of a communication or information covered by the attorney-client privilege.” Rule
502(a) provides that if a “disclosure” of attorney-client communication “is made in a federal
Case 4:23-cv-03433-HSG Document 125 Filed 10/21/25 Page 5 of 8

6
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
United States District Court
Northern District of California
Under California law, attorney-client privilege “may be waived impliedly or by disclosure
of the subject communication.” Transamerica Title Ins. Co. v. Superior Ct., 188 Cal. App. 3d
1047, 1052 (1987). California Evidence Code Section 912(a) provides that the right of any person
to claim attorney-client privilege “is waived with respect to a communication protected by the
privilege if any holder of the privilege, without coercion, has disclosed a significant part of the
communication or has consented to disclosure made by anyone.” “What constitutes a significant
part of the communication is a matter of judicial interpretation.” Transamerica, 188 Cal. App. 3d
at 1052. “Privileged communications do not become discoverable simply because they are related
to issues raised in the litigation.” Id. at 1053; see Garcia v. Progressive Choice Ins. Co., No. 11-
CV-466, 2012 WL 3113172, at *4 (S.D. Cal. July 30, 2012) (quotation marks omitted) (“[A]
waiver under Evidence Code section 912 relates to the particular communication which has been
revealed and not to all communications concerning the subject matter of the lawsuit.”). Privilege
may be waived by implication if the holder of the privilege “has put the otherwise privileged
communication directly at issue and that disclosure is essential for a fair adjudication of the
action.” S. Cal. Gas Co. v. Pub. Utils. Comm’n, 50 Cal. 3d 31, 40 (1990). Plaintiff contends that
Mr. Campinha-Bacote’s statements in his declarations—that he was “aware” that the Stock Option
Agreement was never approved and that he was “informed” and “believed” that Plaintiff had tried
to undermine the Board—amount to a waiver of attorney-client privilege regarding his
communications with Defendants regarding these topics. ECF No. 114 at 2. Plaintiff’s claim that
“Campinha-Bacote has obviously communicated with the Board about these matters”
proceeding … and waived the attorney-client privilege or work-product protection,” privilege as to
undisclosed communication or information is also waived if “(1) the waiver is intentional; (2) the
disclosed and undisclosed communications or information concern the same subject matter; and
(3) they ought in fairness to be considered together.” Rule 502(f) provides that, “notwithstanding
Rule 501, Rule 502 applies even if state law provides the rule of decision.” Although Rule 502
has been interpreted to establish that “the question of whether [attorney-client privilege] is waived
is governed by federal law,” this Court reads Rule 502(a) as limiting the scope of a waiver of
attorney-client privilege, not as determining if there has been a waiver in the first instance.
AdTrader, Inc. v. Google LLC, 405 F. Supp. 3d 862, 866 (N.D. Cal. 2019). That is, if otherwise
privileged material is disclosed, that disclosure would only waive additional, undisclosed
communications if the three criteria of Rule 502(a) were met. See Rule 502 (Advisory Committee
Notes) (“Subdivision (a) provides that if a waiver is found, it applies only to the information
disclosed, unless a broader waiver is made necessary by the holder’s intentional and misleading
use of privileged or protected communications or information.”).
Case 4:23-cv-03433-HSG Document 125 Filed 10/21/25 Page 6 of 8

7
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
United States District Court
Northern District of California
notwithstanding, Plaintiff does not identify any specific “communications” Mr. Campinha-Bacote
disclosed or otherwise put at issue that could have waived privilege. Id. Mr. Campinha-Bacote’s
general statements that he is aware of Defendants’ main defenses in this action does not constitute
a waiver of attorney-client privilege regarding his communications with Defendants. Furthermore,
as discussed below, as Plaintiff has or will be deposing several of Defendants’ Board members
and will be able to question them about the Stock Option Agreement and Plaintiff’s relationship
with the Board, there is no indication deposing Mr. Campinha-Bacote “is essential for a fair
adjudication of the action,” particularly in light of Defendants’ agreement not to rely on Mr.
Campinha-Bacote’s testimony at summary judgment or trial. S.Ca. Gas Co., 50 Cal. at 40.
In addition to determining that Plaintiff has not demonstrated Mr. Campinha-Bacote
waived attorney-client privilege with regard to his communications with Defendants’ Board and
employees, the Court finds that the discovery Plaintiff seeks from Mr. Campinha-Bacote is not
“proportional to the needs of the case” and may be “obtained from some other source that is …
less burdensome.” Fed. R. Civ. P. 26(b). As Defendants argue, Plaintiff has deposed or will
depose two current directors of Oura Health’s Board (both of whom joined the Board before Mr.
Campinha-Bacote started working for Defendants), Oura Health’s COO and former acting CEO,
and Defendants’ 30(b)(6) witness. ECF No. 114 at 4. Plaintiff has also noticed subpoenas on
other former Board members. Id. As Defendants acknowledge, information regarding
Defendants’ claim that Plaintiff has allegedly attempted to undermine the Board and whether Oura
Health’s Board knew of or approved the Stock Option Agreement are both “certainly important to
this case.” Id. at 5. But Defendants will be able to obtain information regarding these “important”
issues from other witnesses and there is no indication that Mr. Campinha-Bacote has non-
duplicative, non-privileged information that is important to advance the litigation.
Plaintiff’s requests to depose Mr. Campinha-Bacote and for Defendants to produce Mr.
Campinha-Bacote’s “communications with current and former Board members and Oura
employees about” the allegations in Mr. Campinha-Bacote’s declarations are accordingly denied.
This denial is without prejudice to Plaintiff renewing his request if subsequent discovery reveals
that Mr. Campinha-Bacote has non-privileged communications or documents that are relevant to
Case 4:23-cv-03433-HSG Document 125 Filed 10/21/25 Page 7 of 8

8
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
United States District Court
Northern District of California
this case and not unreasonably cumulative or duplicative, or if Plaintiff identifies “particular
communication[s]” that waived attorney-client privilege. Garcia, 2012 WL 3113172, at *4.
To ameliorate concerns regarding fairness, the Court holds Defendants to their agreement
to “not rely on any testimony from Mr. Campinha-[Bacote] regarding the validity of the [Stock]
Option Agreement” or “regarding Plaintiff’s friction with the board at summary judgment or at
trial.” ECF Nos. 114 at 5, 114-2 at 2.
IT IS SO ORDERED.
Dated: October 21, 2025
LISA J. CISNEROS
United States Magistrate Judge
Case 4:23-cv-03433-HSG Document 125 Filed 10/21/25 Page 8 of 8